OSTX vs OTLK

OS Therapies Incorporated vs Outlook Therapeutics, Inc. — Valuation Comparison 2026

OSTX

Biotechnology
OS Therapies Incorporated
Quality
3.1
out of 10
Value Trap
12
SAFE
Price
$1.98
Last close
Models
6/13
Active
VS

OTLK

Biotechnology
Outlook Therapeutics, Inc.
Quality
3.7
out of 10
Value Trap
30
LOW
Price
$0.74
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType OSTX Fair ValueOSTX Upside OTLK Fair ValueOTLK Upside
Bayesian DCF Intrinsic $0.52 -74.0% $0.13 -83.0%
Earnings Power Value Intrinsic $0.17 -35.9%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $2.10 +5.9% $1.10 +49.2%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for OSTX vs OTLK — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

OSTX vs OTLK — Which Stock Is More Undervalued?

OTLK scores higher with a 3.7/10 quality rating vs OSTX's 3.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing OS Therapies Incorporated (OSTX) and Outlook Therapeutics, Inc. (OTLK) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

OSTX currently trades at $1.98 with a QOC of 3.1/10, while OTLK trades at $0.74 with a QOC of 3.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).